If you work on the front lines of medical care, treating patients with hepatitis, you may not have time to review all the hepatitis research that enters the medical literature every month. Here’s a quick look at some notable news items and journal articles published over the past month, which cover a variety of the major hepatitis viruses.
Sequential therapy with pegylated interferon after long-term–nucleoside/nucleotide analog therapyand may represent a treatment option to promote HBsAg loss, a recent study revealed.
Researchers in Egypt say that combining serum microRNAs with baseline predictors couldfor staging hepatitis C virus (HCV)-associated liver fibrosis.
Patients with acute HBV infection who also have prodromal fever, which isdue to HBV mutations, are at high risk for acute liver failure, and these patients should be treated with special care, a recent study found.
Iranian researchers found thatamong chronic HBV phases and say this difference may help to develop new precise and noninvasive methods to determine the progression of disease in chronic HBV patients.
A study in Hepatology found that the protein arginine methyltransferase 5via epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation.
Chronic hepatitis C virus (HCV) patients in Chinathat was lower during and after combination therapy, regardless of treatment response. Immunosuppression was higher in patients with sustained viral response than in those without SVR at the end of follow-up.
Hepatoblasts derived from human embryonic stem cells are, according to a study in Hepatology.
A study of U.S. veterans found that, even in the setting of isolated anti–hepatitis B core antigen with or without accompanying hepatitis, can occur. The authors said the occurrence of accompanying severe hepatitis was rare, however.
A study in Italy found that an elevated fibrosis-4 index turned out to bein patients with chronic HCV. The investigators said the assessment of FIB-4 in HCV RNA-positive individuals may help in identifying the highest Hierarchical Condition Categories–risk individuals who need anti-HCV treatment most urgently.
Despite the eradication of HCV transmission by blood products, HCV infectionin Europe, according to an epidemiological study in Infectious Agents and Cancer.